Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
Abstract Aims We aimed to examine efficacy and safety outcomes of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) for the treatment of heart failure (HF), especially in patients with heart failure with preserved ejection fraction (HFpEF). Methods and results PubMed, Web of Science, and Cochrane Li...
Saved in:
Main Authors: | Yang Cao, Pengxiao Li, Yi Li, Yaling Han |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.13905 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure
by: Anastasia D. Egorova, et al.
Published: (2022-06-01) -
Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
by: Eiichi Akiyama, et al.
Published: (2020-06-01) -
Economic impact of heart failure with preserved ejection fraction: insights from the ALDO‐DHF trial
by: Djawid Hashemi, et al.
Published: (2020-06-01) -
Association of sodium–glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis
by: Michele Maremmani, et al.
Published: (2025-01-01) -
Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01)